Adroit Market Research Global Imbruvica Market Size by Application (Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Waldenstroms Macroglobulinemia, Relapsed/Refractory Marginal Zone Lymphoma and Chronic Graft-Versus-Host-Disease), Region and Forecast 2019 to 2025 Single Use License: US$ 4950 +1 (214) 884-6068 [email protected] www.adroitmarketresearch.com Request Sample Adroit Market Research Imbruvica Market Size and Forecast 2018-2025 • Global Imbruvica market report includes market drivers, opportunity and key industry trends. Furthermore, the report provides an in-depth assessment of the market competition with company profiles of global manufacturers. • The market research report on Imbruvica market evaluates the market demand, adoption rate and trending scenario for the period 2015 to 2025. The report highlights the historic trends from 2015 to 2017 and market forecast from 2019 to 2025. • The global Imbruvica market is projected to witness significant growth, rising with a CAGR of 26.5% over the forecast period. The market is projected to reach USD 31,773.40 million by 2025. • Imbruvica is used for the treatment of Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Waldenström's Macroglobulinemia, Relapsed/Refractory Marginal Zone Lymphoma and Chronic Graft-Versus-Host-Disease. In the U.S. Imbruvica is popularly used for all the above mentioned indications, however in rest of the countries worldwide Imbruvica is majorly used for the treatment of Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia and Waldenström’s Macroglobulinemia. Thus, Chronic Lymphocytic Leukemia is expected to grow at a highest CAGR of 27.3% by 2025. • Imbruvica molecule binds Bruton’s tyrosine kinase (BTK) receptor in B-cells. It is used to treat various types of Leukemia and Lymphoma arising from B-cells. Browse the complete reports/imbruvica-market +1 (214) 884-6068 report [email protected] on @ https://www.adroitmarketresearch.com/industry- www.adroitmarketresearch.com Adroit Market Research Imbruvica Market Size and Forecast 2018-2025 • Global Imbruvica market has been segmented based on application, into Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Waldenström's Macroglobulinemia, Relapsed/Refractory Marginal Zone Lymphoma and Chronic Graft-Versus-Host-Disease. Chronic Lymphocytic Leukemia accounted for the largest segment in 2018, followed by Mantle Cell Lymphoma. Additionally, CLL is also anticipated to outpace other application during the forecast period, growing with a CAGR of 27.3%. • Imbruvica market is spread across the U.S., Europe, China, Japan, India, Southeast Asia and Latin America. U.S. dominated the global Imbruvica market in 2018, with 76.1% market share, however, Europe is expected to show the highest CAGR of 27.6% over the forecast period. • Imbruvica comes under the category of orphan drugs, which affect only a small number of population, i.e., < 5/ 2,000 people in Europe, most often at birth. Around, 4000 to 5000 orphan diseases worldwide, have no treatment options. In Europe, 25-30 million people are reported to be affected by these diseases. • In Europe, pancreatic cancer has the least survival rate among all cancers. Over 95,000 people in Europe die of pancreatic cancer each year; the median survival time at the point of diagnosis with just 4.6 months, patients lose 98% of their healthy life expectancy. +1 (214) 884-6068 [email protected] www.adroitmarketresearch.com Adroit Market Research Key segments of the Imbruvica Market • Application Overview, 2015-2025 (USD Million) • • • • • Mantle Cell Lymphoma Chronic Lymphocytic Leukaemia Waldenström's Macroglobulinemia Relapsed/Refractory Marginal Zone Lymphoma Chronic Graft-Versus-Host-Disease • Regional Overview, 2015-2025 (USD Million) • • • • • • • U.S Europe India Japan China Southeast Asia Central & South America Purchase a single user copy of the Imbruvica Market report @ https://www.adroitmarketresearch.com/researchreport/purchase/839 +1 (214) 884-6068 [email protected] www.adroitmarketresearch.com Adroit Market Research About Us Contact Us Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a market’s size, key trends, participants and future outlook of an industry. We intend to become our clients’ knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code– Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps. Our analysts have tracked high growth markets in chemicals & materials, healthcare & pharmaceuticals, semiconductor & electronics, energy & power, food & retail, consumer goods, technology, and machinery & equipment sectors across the world to identify new opportunities, potential customers, prepare go-to-market (GTM) strategies, identify segments for revenue growth for companies, and many more. US Headquarters 3131 McKinney Ave Ste 600 Dallas, TX 75204 ,U.S.A +1 (214) 884-6068 [email protected] Phone: +1 (214) 884-6068 Email: [email protected] www.adroitmarketresearch.com
Global Imbruvica Market report includes market drivers, opportunity and key industry trends. Furthermore, the report provides an in-depth assessment of the market competition with company profiles of global manufacturers. Imbruvica molecule binds Bruton’s tyrosine kinase (BTK) receptor in B-cells. It is used to treat various types of Leukemia and Lymphoma arising from B-cells. The market research report on Imbruvica market evaluates the market demand, adoption rate and trending scenario for the period 2015 to 2025. The report highlights the historic trends and market forecast from 2019 to 2025. The report studies the current status and future prospects of the market at global as well as country level. The market is segmented on the basis of application and geography. Get more insights at: Global Imbruvica Market 2019-2025 Imbruvica players in the United States include Janssen Pharmaceuticals, Inc. and Pharmacyclics LLC (an AbbVie Company).
© Copyright 2024 Paperzz
